Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 1/20 | 0.48 |
| ▸ | CES2 | O00748 | 2/20 | 0.43 |
| ▸ | POLQ | O75417 | 8/20 | 0.43 |
| ▸ | CTSS | P25774 | 2/20 | 0.37 |
| ▸ | CTSK | P43235 | 1/20 | 0.37 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.36 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.36 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
| ▸ | RXRA | P19793 | 1/20 | 0.35 |
| ▸ | RXRB | P28702 | 1/20 | 0.35 |
| ▸ | RXRG | P48443 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3902853 | 0.95 | DAO (0.49) | DAOCES2POLQCTSSCTSK | |
| SCHEMBL22972987 | 0.87 | DAO (0.51) | DAOCES2POLQCTSSCTSK | |
| SCHEMBL18002039 | 0.86 | CES2 (0.43) | DAOCES2POLQCTSKCYSLTR2 | |
| SCHEMBL18378265 | 0.83 | DAO (0.51) | DAOCES2POLQCYSLTR2CYSLTR1 | |
| SCHEMBL2795028 | 0.81 | GAA (0.47) | DAOCTSSCTSKIDO1S1PR1 | |
| SCHEMBL1993639 | 0.81 | CES2 (0.52) | DAOCES2POLQIDO1AR | |
| SCHEMBL18243408 | 0.81 | DAO (0.52) | DAOCES2POLQCYSLTR2CYSLTR1 | |
| SCHEMBL18242683 | 0.81 | DAO (0.49) | DAOCES2POLQSLC6A4IDO1 | |
| SCHEMBL29172379 | 0.80 | CYSLTR2 (0.51) | DAOCES2POLQCYSLTR2CYSLTR1 | |
| SCHEMBL3535046 | 0.79 | CTSS (0.49) | CTSSCTSKIDO1ARRXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009111501-A1 | DERIVATIVES OF IMIDAZO [4, 5-D] PYRIDAZINE AND THEIR USE AS ANTI-VIRAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-09-11 | — | — | WO | disclosed |
| US-20090226398-A1 | ANTI-VIRAL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | GENELABS TECHNOLOGIES, INC. | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090226398-A1 | ANTI-VIRAL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | MAVS, SARS1, HAVCR2 | DAO 2048/4885CES2 477/4885POLQ 620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.